Product Pathways
BCP0097 PF-2341066,Crizotinib
PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.
BCP0098 PHA665752
PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM.
BCP0115 SGX523
SGX-523, an orally bioavailable small molecule, specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway.
BCP0122 SU-11274
SU11274 is a highly specific inhibitor of c-Met , with in vitro IC50 for the Met enzyme at 0.012 umol/L.
BCP0063 JNJ-38877605
An orally bioavailable, small-molecule c-Met inhibitor.
BCP0096 PF-04217903
PF-04217903(PF04217903),selectively binds to and inhibits mesenchymal epithelial transition (MET or c-Met).
BCP0192 AMG458
AMG458,a potent, selective inhibitor of c-Met, a receptor tyrosine kinase that is often deregulated in cancer.
BCP0263 BMS-2
A cell-permeable pyrrolopyridine-pyridone compound that acts as a potent ATP-competitive inhibitor of Met, Flt-3 and VEGFR2.
BCP0398 AMG208
AMG-208 is a highly selective c-Met inhibitor
BCP0544 PF04217903 mesylate
An orally bioavailabe tyrosine kinase inhibitor, targeting MET (or c-MET)
第一页 1 2 3 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.